An assessment by the Statin Diabetes Safety Task Force: 2014 update

被引:159
作者
Maki, Kevin C. [1 ,2 ]
Ridker, Paul M. [3 ,4 ]
Brown, W. Virgil [5 ]
Grundy, Scott M. [6 ]
Sattar, Naveed [7 ]
机构
[1] Midwest Ctr Metab & Cardiovasc Res, Chicago, IL 60631 USA
[2] Depaul Univ, Chicago, IL 60631 USA
[3] Brigham & Womens Hosp, Boston, MA 02115 USA
[4] Harvard Univ, Sch Med, Boston, MA USA
[5] Emory Univ, Sch Med, Atlanta, GA USA
[6] Univ Texas SW Med Ctr Dallas, Dallas, TX 75390 USA
[7] Univ Glasgow, Glasgow, Lanark, Scotland
关键词
National Lipid; Association; Lipid; Type 2 diabetes mellitus; Statin; Coronary heart disease; 14; RANDOMIZED-TRIALS; NONDIABETIC PATIENTS; INSULIN SENSITIVITY; PRIMARY PREVENTION; LDL CHOLESTEROL; RISK-FACTORS; WEIGHT-LOSS; THERAPY; ATORVASTATIN; ROSUVASTATIN;
D O I
10.1016/j.jacl.2014.02.012
中图分类号
R9 [药学];
学科分类号
100702 [药剂学];
摘要
Statin therapy reduces the risk of myocardial infarction, stroke, and cardiovascular death by 25% to 30% in primary as well as secondary prevention patients. Thus, statins are the pharmacologic therapy of choice for the management of high blood cholesterol levels. Prompted by examination of clinical trial data suggesting a modest, but statistically significant, increase in the incidence of new-onset type 2 diabetes mellitus with statin use, the US Food and Drug Administration in 2012 added a statement to the labels of statin medications indicating that increases in glycated hemoglobin (HbA(1C)) and fasting glucose levels have been reported with statin use. This labeling change has raised questions among clinicians regarding the relative benefits and risks of statin use, both among patients with diabetes mellitus and among those with diabetes risk factors. This 2014 report from the Diabetes Subpanel of the National Lipid Association Expert Panel on Statin Safety reviews the published evidence relating statin use to the hazard for diabetes mellitus or worsening glycemia, examines potential mechanisms that may mediate the relationship between statin use and diabetes mellitus risk, and suggests future research efforts. Given the well-established benefits of statin therapy in the primary and secondary prevention of cardiovascular events among those with indications for treatment, no changes to clinical practice are recommended other than the measurement of HbA(1C) or fasting glucose in those deemed to also be at elevated diabetes risk after initiating statin therapy, and potentially before initiation in selected patients considered to be at elevated risk of developing diabetes. The panel advocates following recommendations from the American Diabetes Association, or other relevant guidelines if outside the United States, for screening and diagnosis as well as lifestyle modification for prevention or delay of diabetes mellitus in those with prediabetes or other risk factors. (C) 2014 National Lipid Association. All rights reserved.
引用
收藏
页码:S17 / S29
页数:13
相关论文
共 56 条
[1]
Rosuvastatin and Atorvastatin: Comparative Effects on Glucose Metabolism in Non-Diabetic Patients with Dyslipidaemia [J].
Abbas, Ahmed ;
Milles, John ;
Ramachandran, Sudarshan .
CLINICAL MEDICINE INSIGHTS-ENDOCRINOLOGY AND DIABETES, 2012, 5 :13-29
[2]
Standards of Medical Care in Diabetes-2014 [J].
不详 .
DIABETES CARE, 2014, 37 :S14-S80
[3]
[Anonymous], DASH DIET WEIGHT LOS
[4]
[Anonymous], CLIN BRIEF DOC END M
[5]
[Anonymous], J AM COLL CARDIOL
[6]
[Anonymous], FDA CHANG LAB STAT D
[7]
[Anonymous], FDA DRUG SAF COMM IM
[8]
Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170 000 participants in 26 randomised trials [J].
Baigent, C. ;
Blackwell, L. ;
Emberson, J. ;
Holland, L. E. ;
Reith, C. ;
Bhala, N. ;
Peto, R. ;
Barnes, E. H. ;
Keech, A. ;
Simes, J. ;
Collins, R. .
LANCET, 2010, 376 (9753) :1670-1681
[9]
Efficacy and safety of cholesterol-lowering treatment: prospective meta-analysis of data from 90,056 participants in 14 randomised trials of statins [J].
Baigent, C ;
Keech, A ;
Kearney, PM ;
Blackwell, L ;
Buck, G ;
Pollicino, C ;
Kirby, A ;
Sourjina, T ;
Peto, R ;
Collins, R ;
Simes, J .
LANCET, 2005, 366 (9493) :1267-1278
[10]
Differing effect of statins on insulin sensitivity in non-diabetics: A systematic review and meta-analysis [J].
Baker, William L. ;
Talati, Ripple ;
White, C. Michael ;
Coleman, Craig I. .
DIABETES RESEARCH AND CLINICAL PRACTICE, 2010, 87 (01) :98-107